Focuses on developing therapies for rare fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd., a dynamic clinical-stage biotech company headquartered in Tel Aviv, Israel, is dedicated to pioneering therapies aimed at combating inflammation and fibrosis. The company specializes in discovering and developing innovative treatments to address significant medical challenges in these areas.
At the forefront of Chemomab Therapeutics' pipeline is CM-101, its lead clinical product candidate. CM-101 is a humanized monoclonal antibody designed to disrupt the critical function of soluble chemokine CCL24. This promising therapy targets conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), offering potential breakthroughs in treating these complex diseases.
Founded in 2011 and originally known as Anchiano Therapeutics Ltd., Chemomab Therapeutics rebranded in March 2021 to reflect its focused mission and strategic vision. The company's commitment to innovation and transformative therapies underscores its role in advancing the field of biotechnology, with a clear emphasis on improving patient outcomes and quality of life.